Opioid and cannabinoid receptor function is modulated by multiple cellular mechanisms;both receptors are critical to a number of physiological processes in health as well as in central nervous system disorders including the development of tolerance, dependence and addiction to drugs of abuse. This application focuses on the modulation of receptor function by direct protein-protein interaction i.e. dimerization. We and others have previously shown that opioid receptors dimerize with each other as well as with other G protein-coupled receptors such as cannabinoid receptors. In order to explore the molecular consequences of heterodimerization in vivo and its relevance to analgesia and addiction, we have initiated studies to characterize the mechanisms that contribute to the regulation of these heteromers. During the previous funding period we have made considerable progress with the characterization of opioid receptor heteromers in endogenous tissue. For this, we generated heteromer-selective antibodies and using them demonstrated that the heteromer levels are significantly upregulated in select brain regions under distinct pathological states. We also showed that these heteromers exhibit distinct signaling. Relatively little is known about the mechanisms regulating opioid receptor heteromer abundance or the functional relevance of heteromer signaling. In this application studies to investigate the mechanisms of regulation of opioid and cannabinoid receptor heteromers and to characterize heteromer-specific signaling are proposed.
Specific aims are:
Aim 1, to explore mechanisms of regulation of G protein-coupled receptor heteromer levels, and Aim 2, to generate, characterize, and validate tools that disrupt heteromers and use them to study heteromer-specific signaling. We describe studies using a combination of state-of-the-art technologies as well as unique reagents to address an emerging concept of disease-state specific heteromer upregulation. This, combined with heteromer-mediated distinct signaling, makes the heteromer an ideal disease-specific drug target. Studies proposed here, in addition to providing fundamental information about heteromer biology, form a foundation for the identification of small drug-like molecules specifically targeting the heteromer. Hence, the studies in this application are novel, pioneering and clinically relevant, and are likely to help i the identification of novel targets and therapeutics for the treatment of a number of brain diseases including drug addiction.

Public Health Relevance

The exposure of opioid or cannabinoid receptors to drugs of abuse (morphine or tetrahydrocannabinol, respectively) initiates a number of biological responses including analgesia and development of tolerance/ addiction. The objective of studies in this grant application is to explore novel mechanisms such as receptor- receptor interactions in order to gain basic information about the early events that modulate receptor function. Furthermore, this information forms a foundation for studies identifying novel therapeutic targets for the treatment of pain and drug addiction.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37DA008863-20
Application #
8635995
Study Section
Molecular Neuropharmacology and Signaling Study Section (MNPS)
Program Officer
Wu, Da-Yu
Project Start
1995-03-15
Project End
2017-03-31
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
20
Fiscal Year
2014
Total Cost
$334,274
Indirect Cost
$134,274
Name
Icahn School of Medicine at Mount Sinai
Department
Pharmacology
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Ferré, Sergi; Casadó, Vicent; Devi, Lakshmi A et al. (2014) G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives. Pharmacol Rev 66:413-34
Gupta, Achla; Gomes, Ivone; Wardman, Jonathan et al. (2014) Opioid receptor function is regulated by post-endocytic peptide processing. J Biol Chem 289:19613-26
Toniolo, Elaine F; Maique, Estêfani T; Ferreira Jr, Wilson A et al. (2014) Hemopressin, an inverse agonist of cannabinoid receptors, inhibits neuropathic pain in rats. Peptides 56:125-31
Kivell, Bronwyn; Uzelac, Zeljko; Sundaramurthy, Santhanalakshmi et al. (2014) Salvinorin A regulates dopamine transporter function via a kappa opioid receptor and ERK1/2-dependent mechanism. Neuropharmacology 86:228-40
Fujita, Wakako; Gomes, Ivone; Devi, Lakshmi A (2014) Revolution in GPCR signalling: opioid receptor heteromers as novel therapeutic targets: IUPHAR review 10. Br J Pharmacol 171:4155-76
Margolis, Elyssa B; Hjelmstad, Gregory O; Fujita, Wakako et al. (2014) Direct bidirectional ?-opioid control of midbrain dopamine neurons. J Neurosci 34:14707-16
Matsumoto, Kenjiro; Narita, Minoru; Muramatsu, Naotaka et al. (2014) Orally active opioid ?/? dual agonist MGM-16, a derivative of the indole alkaloid mitragynine, exhibits potent antiallodynic effect on neuropathic pain in mice. J Pharmacol Exp Ther 348:383-92
Stockton Jr, Steven D; Devi, Lakshmi A (2014) An integrated quantitative proteomics and systems biology approach to explore synaptic protein profile changes during morphine exposure. Neuropsychopharmacology 39:88-103
Yang, Lili; Rozenfeld, Raphael; Wu, Defeng et al. (2014) Cannabidiol protects liver from binge alcohol-induced steatosis by mechanisms including inhibition of oxidative stress and increase in autophagy. Free Radic Biol Med 68:260-7
Gomes, Ivone; Gupta, Achla; Devi, Lakshmi A (2013) G-protein-coupled heteromers: regulation in disease. Methods Enzymol 521:219-38

Showing the most recent 10 out of 11 publications